

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 March 2005 (10.03.2005)

PCT

(10) International Publication Number
WO 2005/021508 A1

(51) International Patent Classification⁷: **C07D 213/82**,
401/12, 417/12, C07C 235/60, C07D 257/04, 213/65,
213/64, C07C 233/87, A61K 31/44, 31/444, 31/166, A61P
29/00

and Development, Nagoya, Pfizer Japan Inc., 2, Aza
5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393
(JP).

(21) International Application Number:
PCT/IB2004/002735

(74) Agent: **FULLER, Grover, F., Jr.**; c/o SIMPSON, Alison,
Urquhart-Dykes & Lord LLP, 30 Welbeck Street, London
W1G 8ER (GB).

(22) International Filing Date: 23 August 2004 (23.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/500,131 3 September 2003 (03.09.2003) US

(71) Applicant (for all designated States except JP, US):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(71) Applicant (for JP only): **PFIZER JAPAN, INC.** [JP/JP];
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,
Tokyo 151-8589 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YAMAGISHI,**
Tatsuya [JP/JP]; c/o Pfizer Global Research and De-
velopment, Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi,
Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **OKU-**
MURA, Yoshiyuki [JP/JP]; c/o Pfizer Global Research
and Development, Nagoya, Pfizer Japan Inc., 2, Aza
5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393
(JP). **NUKUI, Seiji** [JP/JP]; Pfizer Global Research and
Development, Combinatorial Chemistry Technology,
10614 Science Center Drive, San Diego, CA 92121 (JP).
NAKAO, Kazunari [JP/JP]; c/o Pfizer Global Research

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS



(57) Abstract: This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like; B represents an aryl or the like; E represents a 1,4-phenylene group; R¹ and R² independently represent a hydrogen atom or the like; R³ and R⁴ independently represent a hydrogen atom or the like; R⁵ represents -CO₂H or the like; R⁶ represents an alkyl group having from 1 to 6 carbon atoms or the like; X represents a methylene group or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. The compounds act as antagonists of the prostaglandin E2 receptor. This invention also provides a pharmaceutical composition comprising the above compound.